What is QT interval prolongation?

Journal of Family Practice

Volumn 54, Issue 6 SUPPL., 2005, Pages

  Vorchheimer, David A ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMIODARONE; ANTIARRHYTHMIC AGENT; ANTIFUNGAL AGENT; BEPRIDIL; DIGITALIS; DISOPYRAMIDE; MACROLIDE; NEUROLEPTIC AGENT; POTASSIUM CHANNEL HERG; PRENYLAMINE; PROCAINAMIDE; QUINIDINE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; SOTALOL; TRICYCLIC ANTIDEPRESSANT AGENT;

BRADYCARDIA; CARDIOMYOPATHY; DRUG INTERACTION; ELECTROLYTE DISTURBANCE; GENE MUTATION; HEART ARRHYTHMIA; HEART ATRIUM FIBRILLATION; HEART DISEASE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPOKALEMIA; INTRAVENOUS ADMINISTRATION; ISCHEMIC HEART DISEASE; LONG QT SYNDROME; MORTALITY; QT PROLONGATION; REVIEW; RISK FACTOR; SEX DIFFERENCE; SUBARACHNOID HEMORRHAGE; SUDDEN DEATH; TORSADE DES POINTES; FEMALE; MALE; PATHOPHYSIOLOGY;

FEMALE; HUMANS; LONG QT SYNDROME; MALE; RISK FACTORS; TORSADES DE POINTES;

EID: 20444406844     PISSN: 00943509     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (14)

1. Cubeddu LX. QT prolongation and fatal arrhythmias: a review of clinical implications and effects of drugs. Am J Ther. 2003;10:452-457.
2. Al-Khatib SM, LaPointe NM, Kramer JM, Califf RM. What clinicians should know about the QT interval. JAMA. 2003;289:2120-2127.
3. Liu BA, Juurlink DN. Drugs and the QT interval - caveat doctor. N Engl J Med. 2004;351:1053-1056.
4. Roden DM. Drug-induced prolongation of the QT interval. N Engl J Med. 2004-350:1013-1022.
5. Moss AJ, Robinson J. Clinical features of the idiopathic long QT syndrome. Circulation. 1992;85(suppl):I140-I144.
6. Ebert SN, Liu XK, Woosley RL. Female gender as a risk factor for drug-induced cardiac arrhythmias: evaluation of clinical and experimental evidence. J Womens Health. 1998;7:547-557.
7. Makkar RR, Fromm BS, Steinman RT, Meissner MD, Lehmann MH. Female gender as a risk factor for torsades de pointes associated with cardiovascular drugs. JAMA. 1993;270:2590-2597.
8. Zeltser D, Justo D, Halkin A, Prokhorov V, Heller K, Viskin S. Torsade de pointes due to noncardiac drugs: most patients have easily identifiable risk factors. Medicine (Baltimore). 2003;82:282-290.
9. Shah RR. Drug-induced prolongation of the QT interval: regulatory dilemmas and implications for approval and labelling of a new chemical entity. Fundam Clin Pharmacol. 2002;16:147-156.
10. Committee for Proprietary Medicinal Products (CPMP). The European Agency for the Evaluation of Medicinal Products. Points to Consider: The Assessment of the Potential for QT Interval Prolongation by Non-cardiovascular Medicinal Products. CPMP/986/96. 1997. Available at: http://www.emea.eu.int/pdfs/ human/swp/098696en.pdf. Accessed: November 15, 2004.
11. Funck-Brentano C, Jaillon P. Rate-corrected QT interval: techniques and limitations. Am J Cardiol. 1993;72:17B-22B.
12. Moss AJ. Measurement of the QT interval and the risk associated with QTc interval prolongation: a review. Am J Cardiol. 1993;72:23B-25B.
13. Moss AJ, Daubert JP, Images in clinical medicine. Internal ventricular defibrillation. N Engl J Med. 2000;342:398.
14. Montanez A, Ruskin JN, Hebert PR, Lamas GA, Hennekens CH. Prolonged QTc interval and risks of total and cardiovascular mortality and sudden death in the general population: a review and qualitative overview of the prospective cohort studies. Arch Intern Med. 2004;164:943-948.